FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Elisa Giovannetti

Research Profile

Chemicals & Drugs

Disorders

Anatomy

Tumor Cell Line

Physiology

Procedures

Antineoplastic Combined Chemotherapy Protocols

Concepts & Ideas

Treatment Outcome

Co-author Network

Publications

TOP 3
S Caponi; N De Lio; Alfredo Falcone; A E Frampton; Nicola Funel; U Boggi; L R Jiao; G Kazemier; G A Meijer; F Mosca; G J Peters; L Santarpia; A G Van der Velde; E Vasile; Hendrik Verheul; Elisa Giovannetti
The good, the bad and the ugly: a tale of miR-101, miR-21 and miR-155 in pancreatic intraductal papillary mucinous neoplasms.
Mina Maftouh; Godefridus J Peters; Amir Avan; Elena Galvani; Elisa Giovannetti
Molecular Mechanisms Underlying the Role of MicroRNAs in Resistance to Epidermal Growth Factor Receptor-Targeted Agents and Novel Therapeutic Strategies for Treatment of Non-Small-Cell Lung Cancer.
Elena Galvani; Elisa Giovannetti; Leticia G Leon; Marco Mor; Roberta Alfieri; Andrea Ardizzoni; Caterina Carmi; Andrea Cavazzoni; Henk Dekker; Pier Giorgio Petronini; Francesca Saccani; Godefridus J Peters
Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Elisa Giovannetti (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: S Caponi; N De Lio; Alfredo Falcone; A E Frampton; Nicola Funel; U Boggi; L R Jiao; G Kazemier; G A Meijer; F Mosca; G J Peters; L Santarpia; A G Van der Velde; E Vasile; Hendrik Verheul; Elisa Giovannetti
The good, the bad and the ugly: a tale of miR-101, miR-21 and miR-155 in pancreatic intraductal papillary mucinous neoplasms.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2013;24(3):734-41.
2013: Mina Maftouh; Godefridus J Peters; Amir Avan; Elena Galvani; Elisa Giovannetti
Molecular Mechanisms Underlying the Role of MicroRNAs in Resistance to Epidermal Growth Factor Receptor-Targeted Agents and Novel Therapeutic Strategies for Treatment of Non-Small-Cell Lung Cancer.
Critical reviews in oncogenesis 2013;18(4):317-26.
2013: Elena Galvani; Elisa Giovannetti; Leticia G Leon; Marco Mor; Roberta Alfieri; Andrea Ardizzoni; Caterina Carmi; Andrea Cavazzoni; Henk Dekker; Pier Giorgio Petronini; Francesca Saccani; Godefridus J Peters
Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer.
Neoplasia (New York, N.Y.) 2013;15(1):61-72.
2013: Elisa Giovannetti; Godefridus J Peters
Development of new molecular agents targeting key signalling pathways activated by growth factors in human cancer.
Current pharmaceutical design 2013;19(5):807.
2013: Amir Avan; Adam E Frampton; Nicola Funel; Mina Maftouh; Francesco Nicolini; Serena Pelliccioni; Godefridus J Peters; Karl Quint; Gerrit J Schuurhuis; Elisa Giovannetti
Enhancement of the antiproliferative activity of gemcitabine by modulation of c-Met pathway in pancreatic cancer.
Current pharmaceutical design 2013;19(5):940-50.
2013: Elisa Giovannetti; Richard Honeywell; M Labots; J S W Lind; H Dekker; E Galvani; R Sciarrillo; Egbert F Smit; Hendrik Verheul; Godefridus J Peters
Molecular mechanisms and modulation of key pathways underlying the synergistic interaction of sorafenib with erlotinib in non-small-cell-lung cancer (NSCLC) cells.
Current pharmaceutical design 2013;19(5):927-39.
2013: Elena Galvani; Elisa Giovannetti; Silvia La Monica; Marco Mor; Godefridus J Peters; Pier Giorgio Petronini; Marcello Tiseo; Mara Bonelli; Andrea Cavazzoni; Claudia Fumarola; Maricla Galetti; Roberta Alfieri; Andrea Ardizzoni
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer.
Current pharmaceutical design 2013;19(5):818-32.
2012: Godefridus J Peters; Elisa Giovannetti
Highlights from the latest articles in pharmacogenomics of irinotecan/cisplatin toxicity.
Pharmacogenomics 2012;13(13):1445-7.
2012: Marcello Tiseo; Andrew Vincent; Fausto Barbieri; Jacobus A Burgers; Andrea Camerini; Francesco Di Costanzo; Elisa Giovannetti; Godefridus J Peters; Egbert F Smit; Carmelo Tibaldi; Andrea Ardizzoni
Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin.
Lung cancer (Amsterdam, Netherlands) 2012;78(1):92-9.
2012: Elena Galvani; Godefridus J Peters; Elisa Giovannetti
EGF receptor-targeted therapy in non-small-cell lung cancer: role of germline polymorphisms in outcome and toxicity.
Future oncology (London, England) 2012;8(8):1015-29.
2012: Amir Avan; Francesco Crea; Romano Danesi; Nicola Funel; Elena Galvani; Richard J Honeywell; Victor E Marquez; Elisa Paolicchi; Godefridus J Peters; Elisa Giovannetti
Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells.
Molecular cancer therapeutics 2012;11(8):1735-46.
2012: Elisa Giovannetti; Tommaso De Pas; Francesca Toffalorio; Godefridus J Peters
Pharmacogenetics of conventional chemotherapy in non-small-cell lung cancer: a changing landscape?
Pharmacogenomics 2012;13(9):1073-86.
2012: Elisa Giovannetti; Giovanni Codacci-Pisanelli; Godefridus J Peters
TFAP2E-DKK4 and chemoresistance in colorectal cancer.
The New England journal of medicine 2012;366(10):966; author reply 966.
2012: Carmelo Tibaldi; Marcello Tiseo; A Ardizzoni; M Bartolotti; F Cappuzzo; A D'Incecco; Elisa Giovannetti; Richard Honeywell; L G Leon; N Loosekoot; Godefridus J Peters
Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2012;23(3):670-7.
2012: Fedro Alessandro Peccatori; B Pistilli; Hatem Azim; G Bellettini; Giovanni Codacci-Pisanelli; Giuseppe Curigliano; Elisa Giovannetti; Aron Goldhirsch; N Losekoot; G J Peters
"The only thing I know is that I know nothing": 5-fluorouracil in human milk.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2012;23(2):543-4.
2012: Elisa Giovannetti; Romano Danesi; Ayse Erozenci; Jorn Smit; Godefridus J Peters
Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice.
Critical reviews in oncology/hematology 2012;81(2):103-22.
2012: Jih-Hsiang Lee; Paul S Meltzer; Iacopo Petrini; Seth M Steinberg; Johannes Voortman; Qiuyan Wang; Yisong Wang; Yonghong Wang; Nicola Funel; Elisa Giovannetti; Jin-Hyeok Hwang; Giuseppe Giaccone
Loss of 18q22.3 involving the carboxypeptidase of glutamate-like gene is associated with poor prognosis in resected pancreatic cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(2):524-33.
2012: Elisa Giovannetti; Leticia G Leon; Vittorio Perrone; Luca Pollina; Hiroko Sudo; Arjan van der Velde; Enrico Vasile; Amir Avan; Ugo Boggi; Daniela Campani; Sara Caponi; Nelide De Lio; Alfredo Falcone; Nicola Funel; Valentina Gallá; Godefridus J Peters
High-throughput microRNA (miRNAs) arrays unravel the prognostic role of MiR-211 in pancreatic cancer.
PloS one 2012;7(11):e49145.
2012: Lale Erdem; Elisa Giovannetti; Richard Honeywell; Leticia G Leon; Godefridus J Peters
Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib.
Current topics in medicinal chemistry 2012;12(15):1649-59.
2012: Maha Elnaggar; Elisa Giovannetti; Godefridus J Peters
Molecular targets of gemcitabine action: rationale for development of novel drugs and drug combinations.
Current pharmaceutical design 2012;18(19):2811-29.
2011: Jasmina Hodzic; Auke D Adema; Begona Diosdado Calvo; Elisa Giovannetti; Begoňa Diosdado; Godefridus J Peters
Regulation of deoxycytidine kinase expression and sensitivity to gemcitabine by micro-RNA 330 and promoter methylation in cancer cells.
Nucleosides, nucleotides & nucleic acids 2011;30(12):1214-22.
2011: Richard J Honeywell; Elisa Giovannetti; Godefridus J Peters
Determination of the phosphorylated metabolites of gemcitabine and of difluorodeoxyuridine by LCMSMS.
Nucleosides, nucleotides & nucleic acids 2011;30(12):1203-13.
2011: Elisa Giovannetti; Leticia G Leon; Matteo Lucchesi; Andrea Mambrini; Paola Pacetti; Godefridus J Peters; Michele Reni; Enrico Vasile; Stefano Cereda; Nicola Funel; Michele Ghidini; Maurizio Cantore
Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy.
Pharmacogenomics 2011;12(12):1641-52.
2011: Elisa Giovannetti; L G Leon; E Lorenzi; C Alecci; Y G Assaraf; Annarita Destro; F Giancola; L Gianoncelli; M Roncalli; A Santoro; Kees Smid; Paolo Andrea Zucali; Godefridus J Peters
Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin.
British journal of cancer 2011;105(10):1542-53.
2011: Carlotta Granchi; Mario Lanza; Antonio Lucacchini; Marco Macchia; Adriano Martinelli; Laura Betti; Alessio De Simone; Gino Giannaccini; Elisa Giovannetti; Godefridus J Peters; Sarabindu Roy; Irene Salvetti; Rocco Sciarrillo; Tiziano Tuccinardi; Filippo Minutolo
N-Hydroxyindole-based inhibitors of lactate dehydrogenase against cancer cell proliferation.
European journal of medicinal chemistry 2011;46(11):5398-407.
2011: Elena Galvani; Godefridus J Peters; Elisa Giovannetti
Thymidylate synthase inhibitors for non-small cell lung cancer.
Expert opinion on investigational drugs 2011;20(10):1343-56.
2011: Niccola Funel; Elisa Giovannetti; Franco Mosca; Luca E Pollina; Ugo Boggi; Marco Del Chiaro; Daniela Campani
Critical role of laser microdissection for genetic, epigenetic and proteomic analyses in pancreatic cancer.
Expert review of molecular diagnostics 2011;11(7):695-701.
2011: Paolo Andrea Zucali; Elisa Giovannetti; Annarita Destro; Manlio Mencoboni; Giovanni Luca Ceresoli; Letizia Gianoncelli; Elena Lorenzi; Fabio De Vincenzo; Matteo Simonelli; Matteo Perrino; Andrea Bruzzone; Erik Thunnissen; Gianni Tunesi; Laura Giordano; Massimo Roncalli; Godefridus J Peters; Armando Santoro
Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(8):2581-90.
2011: Tommaso De Pas; Francesca Toffalorio; Elisa Giovannetti; Davide Radice; Francesca Russo; Ilaria Angeli; Giulia Calamai; Gianluca Spitaleri; Chiara Catania; Cristina Noberasco; Alessandra Milani; Giuseppe Pelosi; Romano Danesi; Filippo de Braud
Optimizing pemetrexed-gemcitabine combination in patients with advanced non-small cell lung cancer: a pharmacogenetic approach.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2011;6(4):768-73.
2011: Carlotta Granchi; Sarabindu Roy; Chiara Giacomelli; Marco Macchia; Tiziano Tuccinardi; Adriano Martinelli; Mario Lanza; Laura Betti; Gino Giannaccini; Antonio Lucacchini; Nicola Funel; Leticia G León; Elisa Giovannetti; Godefridus J Peters; Rahul Palchaudhuri; Emilia C Calvaresi; Paul J Hergenrother; Filippo Minutolo
Discovery of N-hydroxyindole-based inhibitors of human lactate dehydrogenase isoform A (LDH-A) as starvation agents against cancer cells.
Journal of medicinal chemistry 2011;54(6):1599-612.
2011: Leticia G León; Elisa Giovannetti; Claudia Alecci; Fiorella Giancola; Niccola Funel; Paolo Zucali; Godefridus J Peters; José M Padrón
Antiproliferative effects of novel aliphatic acetogenin analogs against aggressive solid tumor cell lines.
In vivo (Athens, Greece) 2011;25(2):203-7.
2011: Fleur Broekman; Elisa Giovannetti; Godefridus J Peters
Tyrosine kinase inhibitors: Multi-targeted or single-targeted?
World journal of clinical oncology 2011;2(2):80-93.
2011: Clara Lemos; Elisa Giovannetti; Paolo A Zucali; Yehuda G Assaraf; George L Scheffer; Tahar van der Straaten; Armida D'Incecco; Alfredo Falcone; Henk-Jan Guchelaar; Romano Danesi; Armando Santoro; Giuseppe Giaccone; Carmelo Tibaldi; Godefridus J Peters
Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients.
Pharmacogenomics 2011;12(2):159-70.
2011: Irene V Bijnsdorp; Elisa Giovannetti; Godefridus J Peters
Analysis of drug interactions.
Methods in molecular biology (Clifton, N.J.) 2011;731():421-34.
2011: Nicola Funel; Elisa Giovannetti; Mariangela Morelli; Franco Mosca; Luca Pollina; Ugo Boggi; Andrea Cavazzana; Marco Del Chiaro; Daniela Campani
Loss of heterozygosity status of D9S105 marker is associated with downregulation of Krüppel-like factor 4 expression in pancreatic ductal adenocarcinoma and pancreatic intraepithelial lesions.
Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 2011;11(1):30-42.
2011: Elisa Giovannetti; Lale Erdem; Efnan Olcay; Leticia G Leon; Godefridus J Peters
Influence of polymorphisms on EGFR targeted therapy in non-small-cell lung cancer.
Frontiers in bioscience : a journal and virtual library 2011;16():116-30.
2010: Francesca Toffalorio; Tommaso De Pas; Elisa Giovannetti
Differences of gene expression in non-small cell lung cancer: are histology, tumor site, and methodology relevant?
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2010;5(8):1310-1; author reply 1311.
2010: Sara Nannizzi; Gareth J Veal; Elisa Giovannetti; Valentina Mey; Simona Ricciardi; Christopher J Ottley; Mario Del Tacca; Romano Danesi
Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines.
Cancer chemotherapy and pharmacology 2010;66(3):547-58.
2010: Elisa Giovannetti; L G Leon; S Bertini; M Macchia; F Minutolo; N Funel; C Alecci; F Giancola; Romano Danesi; Godefridus J Peters
Study of apoptosis induction and deoxycytidine kinase/cytidine deaminase modulation in the synergistic interaction of a novel ceramide analog and gemcitabine in pancreatic cancer cells.
Nucleosides, nucleotides & nucleic acids 2010;29(4-6):419-26.
2010: Godefridus J Peters; J Hodzic; B Ortega; Elisa Giovannetti; Auke D Adema; Richard Broekhuizen; G J L Kaspers; Isabelle Hubeek
Methylation specific PCR to characterize methylation of the promoter of deoxycytidine kinase.
Nucleosides, nucleotides & nucleic acids 2010;29(4-6):408-13.
2010: Elisa Giovannetti; Nicola Funel; Godefridus J Peters; Marco Del Chiaro; Leyla A Erozenci; Enrico Vasile; Leticia G Leon; Luca Pollina; Annemieke Groen; Alfredo Falcone; Romano Danesi; Daniela Campani; Hendrik Verheul; Ugo Boggi
MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity.
Cancer research 2010;70(11):4528-38.
2010: Elisa Giovannetti; Paolo A Zucali; Godefridus J Peters; Filippo Cortesi; Armida D'Incecco; Egbert F Smit; Alfredo Falcone; Jacobus A Burgers; Armando Santoro; Romano Danesi; Giuseppe Giaccone; Carmelo Tibaldi
Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib.
Molecular cancer therapeutics 2010;9(3):581-93.
2010: Ilaria Pastina; Elisa Giovannetti; Aldo Chioni; Tristan M Sissung; Francesco Crea; Cinzia Orlandini; Douglas K Price; C Cianci; William D Figg; Sergio Ricci; Romano Danesi
Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients.
BMC cancer 2010;10():511.
2010: Elisa Giovannetti; Richard Honeywell; Axel R Hanauske; Christina Tekle; Bart Kuenen; Jennifer Sigmond; Giuseppe Giaccone; Godefridus J Peters
Pharmacological aspects of the enzastaurin-pemetrexed combination in non-small cell lung cancer (NSCLC).
Current drug targets 2010;11(1):12-28.
2009: Francesco Crea; Elisa Giovannetti; Pier Luigi Zinzani; Romano Danesi
Pharmacologic rationale for early G-CSF prophylaxis in cancer patients and role of pharmacogenetics in treatment optimization.
Critical reviews in oncology/hematology 2009;72(1):21-44.
2009: Robert Mauritz; Elisa Giovannetti; Ines J Beumer; Kees Smid; Cees J van Groeningen; HERBERT PINEDO; Godefridus J Peters
Polymorphisms in the enhancer region of the thymidylate synthase gene are associated with thymidylate synthase levels in normal tissues but not in malignant tissues of patients with colorectal cancer.
Clinical colorectal cancer 2009;8(3):146-54.
2009: Francesco Crea; Elisa Giovannetti; Filippo Cortesi; Valentina Mey; Sara Nannizzi; Marielle I Gallegos Ruiz; Simona Ricciardi; Mario Del Tacca; Godefridus J Peters; Romano Danesi
Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines.
Molecular cancer therapeutics 2009;8(7):1964-73.
2009: Romano Danesi; Giuseppe Pasqualetti; Elisa Giovannetti; Francesco Crea; Giuseppe Altavilla; Mario Del Tacca; Rafael Rosell
Pharmacogenomics in non-small-cell lung cancer chemotherapy.
Advanced drug delivery reviews 2009;61(5):408-17.
2009: Paola Pacetti; Elisa Giovannetti; Andrea Mambrini; Sara Nannizzi; Massimo Orlandi; Roberta Tartarini; Alfonso Del Freo; Mario Del Tacca; Romano Danesi; maurizio cantore
Single nucleotide polymorphisms and clinical outcome in patients with biliary tract carcinoma treated with epirubicin, cisplatin and capecitabine.
Anticancer research 2009;29(5):1835-40.
2009: Cecilia Ceresa; Elisa Giovannetti; Johannes Voortman; Adrie C Laan; Richard Honeywell; Giuseppe Giaccone; Godefridus J Peters
Bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer and blood mononuclear cells.
Molecular cancer therapeutics 2009;8(5):1026-36.
2009: Clara Lemos; Ietje Kathmann; Elisa Giovannetti; Conceição Calhau; G Jansen; Godefridus J Peters
Impact of cellular folate status and epidermal growth factor receptor expression on BCRP/ABCG2-mediated resistance to gefitinib and erlotinib.
British journal of cancer 2009;100(7):1120-7.
2009: Clara Lemos; Ietje Kathmann; Elisa Giovannetti; Jeroen A M Beliën; George L Scheffer; Conceição Calhau; Gerrit Jansen; Godefridus J Peters
Cellular folate status modulates the expression of BCRP and MRP multidrug transporters in cancer cell lines from different origins.
Molecular cancer therapeutics 2009;8(3):655-64.
2009: Romano Danesi; Giuseppe Altavilla; Elisa Giovannetti; Raffael Rosell
Pharmacogenomics of gemcitabine in non-small-cell lung cancer and other solid tumors.
Pharmacogenomics 2009;10(1):69-80.
2008: Clara Lemos; Ietje Kathmann; Elisa Giovannetti; Henk Dekker; George L Scheffer; Conceição Calhau; Gerrit Jansen; Godefridus J Peters
Folate deprivation induces BCRP (ABCG2) expression and mitoxantrone resistance in Caco-2 cells.
International journal of cancer. Journal international du cancer 2008;123(7):1712-20.
2008: C Tekle; Elisa Giovannetti; Jennifer Sigmond; J R Graff; Kees Smid; Godefridus J Peters
Molecular pathways involved in the synergistic interaction of the PKC beta inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells.
British journal of cancer 2008;99(5):750-9.
2008: Paolo Andrea Zucali; M G Ruiz; Elisa Giovannetti; A Destro; M Varella-Garcia; K Floor; Giovanni Luca Ceresoli; J A Rodriguez; Isabella Garassino; P Comoglio; Massimo Roncalli; Armando Santoro; G Giaccone
Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(9):1605-12.
2008: Nicola Funel; Elisa Giovannetti; Marco Del Chiaro; Valentina Mey; Luca E Pollina; Sara Nannizzi; Ugo Boggi; Simona Ricciardi; Mario Del Tacca; Generoso Bevilacqua; Franco Mosca; Romano Danesi; Daniela Campani
Laser microdissection and primary cell cultures improve pharmacogenetic analysis in pancreatic adenocarcinoma.
Laboratory investigation; a journal of technical methods and pathology 2008;88(7):773-84.
2008: Isabelle Hubeek; Elisa Giovannetti; A J F Broekhuizen; M Pastor-Anglada; G J L Kaspers; Godefridus J Peters
Immunocytochemical detection of hENT1 and hCNT1 in normal tissues, lung cancer cell lines, and NSCLC patient samples.
Nucleosides, nucleotides & nucleic acids 2008;27(6):787-93.
2008: Elisa Giovannetti; Harold H J Backus; Dorine Wouters; Godefridus J Peters
Functional inactivity and mutations of p53 differentially affect sensitivity to 5-fluorouracil and antifolate inhibitors of thymidylate synthase (TS) by altering TS levels in colorectal cancer cells.
Nucleosides, nucleotides & nucleic acids 2008;27(6):740-5.
2008: Elisa Giovannetti; Adrie C Laan; E Vasile; C Tibaldi; S Nannizzi; S Ricciardi; Alfredo Falcone; Romano Danesi; Godefridus J Peters
Correlation between cytidine deaminase genotype and gemcitabine deamination in blood samples.
Nucleosides, nucleotides & nucleic acids 2008;27(6):720-5.
2008: Elisa Giovannetti; Clara Lemos; Christina Tekle; Kees Smid; Sara Nannizzi; José A Rodriguez; Simona Ricciardi; Romano Danesi; Giuseppe Giaccone; Godefridus J Peters
Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells.
Molecular pharmacology 2008;73(4):1290-300.
2008: Carmelo Tibaldi; Elisa Giovannetti; Enrico Vasile; Valentina Mey; Adrie C Laan; Sara Nannizzi; Roberta Di Marsico; Andrea Antonuzzo; Cinzia Orlandini; Simona Ricciardi; Mario Del Tacca; Godefridus J Peters; Alfredo Falcone; Romano Danesi
Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(6):1797-803.
2008: Elisa Giovannetti; Dewa G Ugrasena; Eddy Supriyadi; Laura Vroling; Antonino Azzarello; Desiree de Lange; Godefridus J Peters; Anjo J P Veerman; Jacqueline Cloos
Methylenetetrahydrofolate reductase (MTHFR) C677T and thymidylate synthase promoter (TSER) polymorphisms in Indonesian children with and without leukemia.
Leukemia research 2008;32(1):19-24.
2007: Romano Danesi; Giuseppe Pasqualetti; Elisa Giovannetti; Mario Del Tacca
The role of pharmacogenetics in adjuvant treatment of non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2007;2(5 Suppl):S27-30.
2007: Elisa Giovannetti; Valentina Mey; Lucia Loni; Sara Nannizzi; Gemma Barsanti; Grazia Savarino; Simona Ricciardi; Mario Del Tacca; Romano Danesi
Cytotoxic activity of gemcitabine and correlation with expression profile of drug-related genes in human lymphoid cells.
Pharmacological research : the official journal of the Italian Pharmacological Society 2007;55(4):343-9.
2007: Elisa Giovannetti; Harold H J Backus; Dorine Wouters; Carlos G Ferreira; Viola M M van Houten; Ruud H Brakenhoff; M-F Poupon; A Azzarello; HERBERT PINEDO; Godefridus J Peters
Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels.
British journal of cancer 2007;96(5):769-75.
2006: Cataldo Bianco; Elisa Giovannetti; Fortunato Ciardiello; Valentina Mey; Sara Nannizzi; Giampaolo Tortora; Teresa Troiani; Francesco Pasqualetti; Gail Eckhardt; Mario de Liguoro; Simona Ricciardi; Mario Del Tacca; David Raben; Luca Cionini; Romano Danesi
Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(23):7099-107.
2006: Valentina Mey; Elisa Giovannetti; Filippo de Braud; Sara Nannizzi; Giuseppe Curigliano; Fabrizio Verweij; Ottavio De Cobelli; S Pece; Mario Del Tacca; Romano Danesi
In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients.
British journal of cancer 2006;95(3):289-97.
2006: Elisa Giovannetti; Valentina Mey; Sara Nannizzi; Giuseppe Pasqualetti; Mario Del Tacca; Romano Danesi
Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer.
Molecular cancer therapeutics 2006;5(6):1387-95.
2006: Elisa Giovannetti; Romano Danesi; Valentina Mey; Sara Nannizzi; Giuseppe Pasqualetti; Mario Del Tacca
In vitro studies on gemcitabine combinations with other antiblastics.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17 Suppl 5():v17-19.
2006: Elisa Giovannetti; Mario Del Tacca; Valentina Mey; Nicola Funel; Sara Nannizzi; Sergio Ricci; Cinzia Orlandini; Ugo Boggi; Daniela Campani; Marco Del Chiaro; Mauro Iannopollo; Generoso Bevilacqua; Franco Mosca; Romano Danesi
Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine.
Cancer research 2006;66(7):3928-35.
2005: Carmelo Bengala; Valentina Guarneri; Elisa Giovannetti; Monica Lencioni; E Fontana; Valentina Mey; A Fontana; U Boggi; Marco Del Chiaro; Romano Danesi; Sergio Ricci; F Mosca; Mario Del Tacca; Pier Franco Conte
Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma.
British journal of cancer 2005;93(1):35-40.
2005: Elisa Giovannetti; Valentina Mey; Sara Nannizzi; Giuseppe Pasqualetti; Luca Marini; Mario Del Tacca; Romano Danesi
Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells.
Molecular pharmacology 2005;68(1):110-8.
2005: Elisa Giovannetti; Valentina Mey; Romano Danesi; Fulvio Basolo; S Barachini; M Deri; Mario Del Tacca
Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile.
British journal of cancer 2005;92(4):681-9.
2004: Elisa Giovannetti; Valentina Mey; Romano Danesi; Irene Mosca; Mario Del Tacca
Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(9):2936-43.
2003: Marco Macchia; Simone Bertini; Stefano Fogli; Elisa Giovannetti; Filippo Minutolo; Simona Rapposelli; Romano Danesi
Ceramide analogues in apoptosis: a new strategy for anticancer drug development.
Farmaco (Società chimica italiana : 1989) 2003;58(3):205-11.
2003: Marco Macchia; Michela Antonello; Simone Bertini; Valeria Di Bussolo; Stefano Fogli; Elisa Giovannetti; Filippo Minutolo; Simona Rapposelli; Romano Danesi
Conformationally restrained ceramide analogues: effects of lipophilic modifications on the antiproliferative activity.
Farmaco (Società chimica italiana : 1989) 2003;58(1):85-9.
2001: Marco Macchia; Silvia Barontini; Simone Bertini; Valeria Di Bussolo; Stefano Fogli; Elisa Giovannetti; enzo grossi; Filippo Minutolo; Romano Danesi
Design, synthesis, and characterization of the antitumor activity of novel ceramide analogues.
Journal of medicinal chemistry 2001;44(23):3994-4000.